UCLA discovers first stroke rehabilitation drug to repair brain damage

Leading Innovation in Psychiatric Treatment | Alto Neuroscience

We leverage brain biology to develop personalized medicines, helping patients get better faster.

Inventing the future: A neuroscience research roadmap

The past decade of transformative advances in neurotechnology portends an exciting future for neuroscience. This NeuroView charts a strategic path to accelerate and integrate research discovery and speed the development of new cures for human brain disorders.

Precision Medicine in Neuroscience: Tools, Translation, and Implementation: A Workshop

Precision medicine approaches are rapidly transforming neuroscience, driven by advances in genetics, neuroimaging, biomarkers, and data science. These tools enable more refined disease classification, improved diagnosis, and treatments tailored to individual patients across neurological and psychiatric disorders. However, challenges remain in translating these advances into routine research and clinical practice. On March 4–5, the National Academies’ Forum on Neuroscience and Nervous System Disorders, in collaboration with the Forum on Drug Discovery, Development, and Translation and the Roundtable on Genomics and Precision Health, will host a workshop exploring opportunities, challenges, and strategies for integrating precision medicine into neuroscience research and care.

Precision Medicine in Neuroscience: Tools, Translation, and Implementation: A Workshop

Join the web’s most supportive community of creators and get high-quality tools for hosting, sharing, and streaming videos in gorgeous HD with no ads.

Blueprint Neurotech

The Center for Innovative NeuroTech Advancement (CINTA) & NeuroTech Harbor (NTH) announce the Cycle 6 Award Competition supported by the NIH Blueprint MedTech Program. This program is seeking collaborative projects aimed at developing emerging technologies into commercially viable, clinically focused solutions for disorders of the nervous system that are aligned with the mission and interests of the participating NIH institutes and centers.

Motif Neurotech — Therapeutic Brain Computer Interface For Mental Health

We're building devices to help you monitor and regulate your mental health and performance.

Partner with Neuroscience

Partner with J&J Neuroscience to collaborate on licensing, academia, venture deals and shared innovation across Alzheimer’s, Parkinson’s and more.

What Patients Say Works (And Doesn't) for Migraines

For the live-updated, fully-labelled, interactive version of this infographic, click here. Eight of the top ten patient-reported treatments for Migraine are simple lifestyle changes, not drugs. CureTogether – a free resource owned by 23andMe that allows people to share information about their health and treatments – surveyed more than 6,000 people who self-identify as having […]

Dopamine Nation — Anna Lembke, MD

In Dopamine Nation, Dr. Anna Lembke, psychiatrist and author, explores the exciting new scientific discoveries that explain why the relentless pursuit of pleasure leads to pain.

Ramez Naam on Twitter / X

There was a site years ago called CureTogether where patients could share information in a structured way on their disease, regimen, and progress, working towards a sort of bottoms-up clinical trial. 23andMe acquired them and it seems to be mostly dead.— Ramez Naam (@ramez) September 14, 2025

NeuroNYC

As the global leader in finance, policy, art, research, and medicine, the region is well-positioned to lead neurotech. We help foster and promote the local neurotech ecosystem: clinics, companies, funders, labs, and users.

PTI-125 Reduces Biomarkers of Alzheimer’s Disease in Patients

The most common dementia worldwide, Alzheimer’s disease is often diagnosed via biomarkers in cerebrospinal fluid, including reduced levels of Aβ1-42, and increases in total tau and phosphorylated tau-181. Here we describe results of a Phase 2a study of a promising new drug candidate that significantly reversed all measured biomarkers of Alzheimer’s disease, neurodegeneration and neuroinflammation. PTI-125 is an oral small molecule drug candidate that binds and reverses an altered conformation of the scaffolding protein filamin A found in Alzheimer’s disease brain. Altered filamin A links to the α7-nicotinic acetylcholine receptor to allow Aβ42’s toxic signaling through this receptor to hyperphosphorylate tau. Altered filamin A also links to toll-like receptor 4 to enable Aβ-induced persistent activation of this receptor and inflammatory cytokine release. Restoring the native shape of filamin A prevents or reverses filamin A’s linkages to the α7-nicotinic acetylcholine receptor and tolllike receptor 4, thereby blocking Aβ42’s activation of these receptors. The result is reduced tau hyperphosphorylation and neuroinflammation, with multiple functional improvements demonstrated in transgenic mice and postmortem Alzheimer’s disease brain.

Learning What Substance Is Suspected of Causing Alzheimer’s May Throw You Into an Existential Crisis

A surprisingly common substance was found to have a causal relationship with the kind of brain damage associated with Alzheimer's disease.

The Terrorist in the Brain

What can Robin Williams and Bruce Willis teach us about dementia? This article explores the complex biological realities of brain diseases, controversies in Alzheimer's research, the risks of new drugs, and the multi-billion-dollar industry exploiting our fear of cognitive decline.